Related Experiment Videos
[Effect of cefminox on severe infections accompanying hematological diseases]
The Japanese Journal of Antibiotics
|January 1, 1985
Abstract:
A new antibiotic cefminox (CMNX, MT-141) was administered to 54 patients with severe infections accompanying various hematological diseases. The rate of effectiveness was 55.3% on the whole. Mild liver dysfunction was observed in 3 cases, which recovered quickly following the stop of the administration.
Insights
A novel antibiotic, cefminox (CMNX), demonstrated a 55.3% effectiveness rate in treating severe infections in patients with hematological diseases. Mild liver issues were noted in a few cases but resolved upon discontinuation.
Area of Science:
- Infectious Diseases
- Hematology
- Pharmacology
Context:
- Severe infections in patients with hematological diseases pose significant treatment challenges.
- Limited effective therapeutic options are available for these complex cases.
Purpose:
- To evaluate the efficacy and safety of the novel antibiotic cefminox (CMNX) in treating severe infections in patients with hematological diseases.
Summary:
- Cefminox (CMNX, MT-141) was administered to 54 patients suffering from severe infections associated with various hematological conditions.
- An overall effectiveness rate of 55.3% was observed.
- Mild, transient liver dysfunction occurred in 3 patients, resolving after drug cessation.
Impact:
- Cefminox demonstrates potential as a treatment option for severe infections in hematological disease patients.
- Further research is warranted to optimize its use and confirm its safety profile in this vulnerable population.